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Stimuli-responsive local drug molecule delivery
to adhered cells in a 3D nanocomposite scaﬀold†
Andisheh Motealleh, a Rossella De Marcob and Nermin Seda Kehr *a
Drug delivery systems capable of providing controlled and localized drug release are a highly important
tool in the biomedical field because they can provide site-specific, sustained, and controlled drug
release at the place where the drug is most needed, and they allow for significantly lower doses of the
drug at other parts of the body, reducing the drug’s potential side eﬀects. In this respect, we describe
pH-responsive PMO/alginate nanocomposite (NC) scaﬀolds with diﬀerent pH-responsive strengths for
controlled local drug delivery applications. To prepare the PMO/alginate NC scaﬀolds, PMOs were first
loaded with anti-cancer molecules and then coated with a non-biopolymer or a biopolymer, after which
the PMOs were embedded into an alginate network. We found that drug release from the PMOs
was regulated by the pH of the environment and the surface coating of the PMOs due to the diﬀerent pH-
dependent levels of electrostatic interactions between all the charged components of the NC scaﬀolds. The
non-biopolymer-coated formulation of the NC scaﬀold can be utilized to deliver higher dosages of drug
molecules directly to cells, while the biopolymer-coated system is useful for slow and prolonged release of
drugs and for enhanced cell adhesion. Nonetheless, both systems can be utilized, in particular, to deliver
higher dosages of drug molecules directly to cancer cells while delivering less of the drug to healthy cells.
Introduction
Drug delivery systems capable of providing controlled and
localized drug release, often called implantable drug delivery
systems (IDDSs),1,2 are a highly important tool in the biomedical
field because they oﬀer several advantages over conventional drug
administration methods (e.g. the oral and parental route of drug
administration). IDDSs have been designed to provide site-specific,
sustained, and controlled drug release at the location where the drug
is most needed in order to improve patient compliance and to allow
for significantly lower doses of drug at other parts of the body,
reducing the drug’s potential side eﬀects.3,4 Furthermore, IDDSs
allow for the delivery of drugs that cannot and/or should not be
delivered via the oral route, due to their adsorption in the gastro-
intestinal tract, highly toxic side eﬀects, or because they would be
more beneficial with site-specific dosing (e.g. anti-cancer drugs,
steroids, antibiotics).
Nanocontainers and hydrogels represent excellent types of
IDDSs due to their ability to provide biocompatibility, stability,
controlled delivery, and biodegradability.5–7 Hydrogels, which
are crosslinked three-dimensional (3D) polymer networks, are
widely used as 3D cell culture and drug delivery systems in
tissue engineering and biomedical applications.8–10 Hydrogels
improve not only cell adhesion but also drug resistance, and
they provide localized controlled drug delivery due to their
bioadhesive characteristics, hydrophilic nature, injectability
and 3D network.11,12 Furthermore, polymer-based nanoparticles,
e.g. polylactic-co-glycolic acid (PLGA) or polylactic acid (PLA),
alginate, liposomes, micelles, and inorganic nanoparticles, have
been intensively studied for their use as drug delivery vehicles.
Among these, porous silica-based nanocontainers are promising
candidates for controlled drug delivery applications due to their
large surface area, narrow pore size distributions, and surfaces that
are easy to functionalize.13–19 Porous silica-based nanocontainers
can encapsulate a wide variety of hydrophobic or hydrophilic
(bio)molecules and protect them against chemical and biological
degradations. Furthermore, simple surface modifications can
improve their interaction with biological systems, reduce any
associated harmful effects, and provide site-specific targeting.
Recent years have seen increased interest in the development
of stimuli-responsive nanoparticle/hydrogel composite systems,
namely nanocomposite (NC) hydrogels, which represent multifunc-
tional biomaterials suitable for tissue engineering and local drug
delivery applications.20,21 For example, Lin et al.22 described bio-
compatible LAPONITEs (LP)-embedded alginate hydrogels for
pH-responsive cationic drug delivery. Gaharwar et al. reported
k-carrageenan-based hydrogels loaded with nanosilicates23 and
injectable stimuli-responsive magnetic nanoparticle-embedded
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poly(N-isopropylacrylamide-co-acrylamide) (poly(NIPAM-co-AM))
hydrogels24 for sustained release of therapeutic biomacromole-
cules. In such systems, the nanoparticle contribution to hydrogel
network improves the mechanical properties of the hydrogel and
increases biomolecule adsorption (e.g. proteins, growth factors)
on the 3D network of the biomaterial due to nanoparticles’ large
surface areas; biomolecule adsorption thereby results in the
sustained release of biomolecules and in enhanced cell adhesive-
ness and cell spreading.
In this context, we have previously reported on polyelectrolyte-
coated zeolite L-embedded alginate hydrogels for pH-responsive
controlled delivery of fluorescent dye molecules to adhered cells.25
However, in that study, to be able to release the organic molecules
from the zeolites L particles, the acidity of the cell culture media
had to be changed by adding an acidic solution; this would clearly
not be applicable in clinical situations. In another contribution,
we described self-assembled monolayers (SAMs) of chiral periodic
mesoporous organosilica (PMO) as a 2D platform for the pH-
responsive delivery of fluorescent dye molecules and drug mole-
cules to adhered healthy and cancer cells.26 The SAMs of the
chiral PMOs showed a greater amount of dye/drug molecules
released in the presence of Colo 818 cancer cells than healthy
fibroblast cells due to the local acidic environment of the cancer
cells. In addition, we showed that the chirality of the PMOs
influenced the amount of cells that adhered, therefore the released
molecules, interacted with diﬀerent amount of cells which allowing
us to tune the extent of local drug delivery.
In this contribution, we aim to combine our previous studies
to design a new NC hydrogel as a 3D platform for pH-responsive
surface-mediated delivery of anti-cancer drug molecules
targeted toward mostly cancer cells (and avoiding healthy cells).
We prepared our pH-responsive NC hydrogel by first loading
anti-cancer molecules into PMOs, then coating the loaded
PMOs with poly-L-lysine (PLL), and finally embedding the
coated and loaded PMOs into an alginate hydrogel network.
The prepared pH-responsive PMO/alginate hydrogel showed
prolonged release of a moderate and high dosage of drug
molecules under physiological and acidic conditions (pH 6.0,
simulating a tumor tissue environment), respectively due to the
diﬀerent pH-dependent levels of electrostatic interactions
between the all charged components of the final NC hydrogel.
Therefore, our pH-responsive PMO/alginate hydrogel was able
to deliver locally more anti-cancer drug molecules to cancer
cells than to healthy cells due to the local acidic environment
generated by the cancer cells.
In this respect, this work has presented a novel strategy for
designing anti-cancer drug-loaded, pH-sensitive NPs, and the
resulting 3D NC hydrogels allow for stimuli-responsive local
drug delivery and enhanced cancer therapy.
Experimental
Materials
Poly-L-lysine (PLL, MW: 30 000–70 000), poly(styrenesulfonate)
(PSS), hexadecyltrimethylammonium bromide (CTAB, 98%),
1,2-bis(trimethoxysilyl)ethane (BTME, 96%), and trypsin were
purchased from Sigma-Aldrich. Doxorubicin (DOX) was purchased
from Sigma-Aldrich. Toluene, ethanol (absolute for analysis),
ammonia solution (32%, pure) and hydrochloric acid (HCl)
(32%, for analysis), were purchased from Merck. Glass plates
(1.8 cm  1.8 cm) were obtained from VWR. The cell medium
(RPMI 1640) supplemented with 1% (v/v) penicillin/streptomycin,
2% L-glutamine, and 10% (v/v) fetal bovine serum (FBS) were
obtained from Biochrom, Germany. Calcein AM (Z96.0% (HPLC))
and propidium iodide (Z94.0% (HPLC)) were purchased
from Sigma-Aldrich. Primary dermal fibroblasts: normal, human,
adult (ATCCs PCS-201-012t) cells were obtained from ATCC.
Human Colo 818 (malignant melanoma) cells were purchased
from DSMZ.
The detail information of how to synthesis the PMO-NH2,
and how to determine the amount of DOX in DOXPMO-NH2 and
later, DOXPMO-(PSS)PLL are mentioned in ESI.†
Loading of DOX into PMO-NH2 (
DOXPMO-NH2)
PMO-NH2 (100 mg) was suspended in 1 mL water and mixed
with 0.9 mM DOX. This reaction mixture was stirred for 1 day
at room temperature. The final product DOXPMO-NH2 was
obtained by centrifugation, washed with water 1, and dried
at room temperature.
General procedure for preparing NC hydrogels of
PMO-(PSS)PLL, DOXPMO-NH2, and
DOXPMO-(PSS)PLL
Stock solutions of alginate (1.25 g) in 100 mL double distilled
water and calcium D-gluconate monohydrate (1.00 g) in 100 mL
double distilled water were prepared. The suspension of
PMO-PSS/PLL, DOXPMO-NH2, and
DOXPMO-PSS/PLL (1 mg) in
calcium D-gluconate monohydrate (1 mL) was sonicated for
20 min and then added into the alginate solution (2 mL) during
vortexing.
General procedure for preparing NC alginate scaﬀolds
of PMO-(PSS)PLL, DOXPMO-NH2, and
DOXPMO-(PSS)PLL
The cross-linked NC alginate hydrogel of PMO-PSS/PLL,
DOXPMO-NH2, and
DOXPMO-PSS/PLL (100 mL) was transferred
into a Teflon container, frozen at 20 1C for 16 h and then
lyophilized in a freeze dryer for 16 h.
DOX release from NC alginate scaﬀolds of DOXPMO-NH2 and
DOXPMO-(PSS)PLL at pH 7.4 and pH 6.0
NC scaﬀolds of DOXPMO-NH2 and
DOXPMO-(PSS)PLL (1 mg mL1)
were suspended in cell culture media at pH 7.4 and in cell
culture media at pH 6.0 (pH 6.0 was obtained by titration with
hydrochloric acid 32 wt% in H2O) and mixed at room tempera-
ture; DOX levels were measured at various time intervals. The
fluorescence intensity of released DOX was measured from the
supernatant taken from the sample. The amount of DOX
released from NC scaﬀolds of DOXPMO-NH2 and
DOXPMO-(PSS)PLL
at pH 7.4 and pH 6.0 was determined by using the formula
from the calibration curve of diﬀerent DOX concentrations:
y = 20 224x + 10 474 (Fig. S1, ESI†).
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General procedure for the cell experiments in NC
alginate scaﬀolds of PMO-(PSS)PLL, DOXPMO-NH2, and
DOXPMO-(PSS)PLL
The healthy fibroblasts and Colo 818 cancer cells were carefully
thawed and suspended in 10% FBS containing cell culture
media (RPMI 1640). Then the cells (ca. 20 000) were separately
seeded onto the NC alginate scaﬀolds of PMO-(PSS)PLL,
DOXPMO-NH2, and
DOXPMO-(PSS)PLL, covered with the cell
culture media at pH 7.4, and incubated for various time
intervals (e.g. from 30 min to 14 days) at 37 1C and 5% CO2.
After the incubation periods, each of the NC scaﬀolds was
washed twice with PBS to remove non-adhered cells. Subse-
quently, NC scaﬀolds were transferred to another cell culture
plate and treated with EDTA (0.04% w/v in PBS, without
Ca2+/Mg2+) with gentle mixing. The cells were counted imme-
diately using a Neubauer chamber (trypan blue solution was
used to detect dead cells).
General procedure for the PrestoBlue assay for cell proliferation
and viability
The cell viability (%) was determined according to the PrestoBlue
cell viability reagent protocol. For this measurement, scaﬀolds in
the presence of cells were incubated for 2 hours, 1 day, 3 days and
7 days at 37 1C with 5% CO2. After each incubation time, the
scaﬀolds were washed with 1 mL PBS solution (2) to remove
unattached cells on scaﬀolds, then they were transferred to a new
cell culture plate and dissolved with 50 mL EDTA (0.04% w/v in
PBS, without Ca2+/Mg2+). The fresh media (200 mL) was added
onto each scaﬀold and mixed with 20 mL per well PrestoBlue
reagent. The samples were incubated for 1 h, then measured at
570 nm.
General procedure for the double staining of cells
with calcein-AM and propidium iodide
Calcein AM/propidium iodide staining were employed to check
the cellular viability or cell death, respectively. For this purpose
1 mM calcein AM and 1.5 mM Propidium Iodide were added at
the same time into DOXPMO-(PSS)/PLL-Alg and DOXPMO-NH2-
Alg scaﬀolds in presence of fibroblast and colo 818 cells (after
7 days of incubation), the samples were kept in incubator at
37 1C and 5% CO2 for 30 min, then they were checked by
fluorescence microscope.
Characterization
The morphology of the PMOs was investigated with scanning
electron microscopy (SEM) using a Zeiss 1540 EsB dual beam
focused ion beam/field emission scanning electron microscope.
Zeta potential measurements and dynamic light scattering (DSL)
were done with a Malvern Zetasizer Nano Series. The rheological
behaviour of each sample was provided by Anton Paar Rheometer.
The ANOVA test was used for statistical analyses. A spectrofluo-
rometer (Fluorolog Horiba Jobin Yvon) was used to determine the
amount of DOX in the PMOs. The occupancy rate of the hydrogels
(how much of the hydrogel surface area was taken up by the
PMOs) was determined using ImageJ software. A time-resolved
spectrofluorometer (Fluorolog Horiba Jobin Yvon) was used to
determine the calibration curve for diﬀerent concentrations of
DOX (emission maximum = 550 nm).
Results and discussion
Preparation of pH responsive PMOs
Synthesis of DOXPMO-NH2 and
DOXPMO-(PSS)PLL were described
previously by us (for details see the ESI†).26 Briefly, we first
synthesized amino-functionalized PMOs (PMO-NH2) and loaded
them with the anti-cancer drug DOX to obtain DOXPMO-NH2. The
drug loading and the encapsulation eﬃciency of doxorubicin in
DOXPMO-NH2 were 44.3%, and 88.6%, respectively, and these
values for DOXPMO-(PSS)PLL were 43.8% and 87.6%, respectively
(for details see the ESI†). The prepared PMO-NH2 and
DOXPMO-NH2
were coated with oppositely charged polyelectrolytes (PSS and
PLL) according to the layer-by-layer (LbL) deposition technique
to obtain PMO-PSS/PLL (as a control) and DOXPMO-PSS/PLL,
respectively and to increase the pH responsiveness of the DOX
release from PMOs. Subsequently, we determined the adsorbed
amount of polymers onto the PMO-NH2 and
DOXPMO-NH2 by
using UV/Vis spectrophotometry (Table S1, ESI†). The content
of drug molecules (DOX) in the pores of DOXPMO-NH2 and
DOXPMO-PSS/PLL was determined using fluorescence spectro-
metry (Fig. S1 and Table S2, ESI†). Almost the same amount of
PSS/PLL was adsorbed onto the PMO-NH2 and
DOXPMO-NH2.
The content of DOX loaded into the DOXPMO-PSS/PLL and
DOXPMO-NH2 was almost same.
The prepared PMO-PSS/PLL, DOXPMO-NH2, and
DOXPMO-PSS/
PLL were characterized by dynamic light scattering (DLS), scanning
electron microscopy (SEM) and zeta-potential. The size of the PMOs
increased after PSS/PLL coating, shown by DLS (Table S3, ESI†). The
SEM images show the spherically shaped DOXPMO-NH2, PMO-PSS/
PLL, and DOXPMO-PSS/PLL (Fig. 1). The change in the zeta potential
was observed after PSS/PLL coating of (PMO-NH2/
DOXPMO-NH2),
demonstrating the successful coating of PMO-NH2/
DOXPMO-NH2
with PSS/PLL (see Table S4 for zeta potential data for each coating,
ESI†).
Preparation of NC scaﬀolds of DOXPMO-NH2 and
DOXPMO-
(PSS)PLL and determining the release of DOX from the
respective pH-responsive NC scaﬀolds
PMO-PSS/PLL, DOXPMO-NH2 and
DOXPMO-PSS/PLL were embedded
into an alginate hydrogel network and freeze-dried to obtain
pH-responsive NC scaﬀolds (PMO-(PSS)PLL-Alg, DOXPMO-NH2-Alg,
and DOXPMO-(PSS)PLL-Alg). The prepared NC scaﬀolds were
Fig. 1 SEM images of DOXPMO-NH2 (A) PMO-(PSS)PLL (B) and
DOXPMO-
(PSS)PLL (C).
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analysed by diﬀerent techniques to determine their morpho-
logical, swelling, degradation, porosity, and rheological, pro-
perties (Fig. 2 and Fig. S2, S3, Tables S5–S9, ESI†).
The 3D porous alginate scaﬀold network and the embedded
PMOs in the alginate scaﬀold wall can be seen in the SEM
images (Fig. 2). The PMO distribution on a 1 mm2 area of each
scaﬀold was determined by ImageJ’s multi-point tool using
SEM images of the respective NC scaﬀolds (Table S5, ESI†). The
quantitative amount of DOXPMO-NH2 and
DOXPMO-PSS/PLL
were almost the same in the respective scaﬀolds, as measured
with fluorescence spectrometry (Table S6, ESI†). The swelling
ratio, degradation behaviour, and porosity of the DOXPMO-
NH2-Alg and
DOXPMO-PSS/PLL-Alg scaﬀolds were determined
and compared with alginate scaﬀolds alone to investigate the
impact of PMOs (Tables S7–S9, ESI†). In general, larger pores
and/or higher porosity can store more water or (bio)molecules,
but they can also result in decreased stability. However, the
PMO-embedded scaffolds exhibited a higher swelling capacity,
higher porosity, and less degradation in comparison to the
alginate scaffold alone, showing that the incorporation of
hydrophilic porous PMOs into the alginate scaffold enhances
the hydrophilicity and mechanical stability of the network.
Rheology measurements were done for Alg and DOXPMO-NH2-
Alg, and DOXPMO-(PSS)PLL-Alg hydrogel. G0 and G00 were done
under constant oscillation conditions (Fig. S2 and S3, ESI†).
G0 or the storage modulus demonstrates elastic stress, G00 or
loss modulus displays viscous stress and apparent viscosity (m)
as a function of angular frequency. The results showed that
alginate hydrogel with presence of PMOs had more viscose
structure than alginate hydrogel itself (Fig. S2, ESI†), because
PMOs serve as cross-linkers like described previously.27 Therefore,
the NC hydrogel had stronger network which produced higher
storage modulus (Fig. S3, ESI†). By adding PMO within hydrogel
network the storage modulus (G0) and the loss modulus (G00) were
increased. G0 was much more than G00 which proves that the
alginate hydrogel and PMO alginate hydrogel are viscoelastic gels.
Furthermore, we observed that DOXPMO-(PSS)PLL-Alg gave higher
values of G0 and G00 than the DOXPMO-NH2-Alg. This data indi-
cating that the electrostatic interaction between DOXPMO-(PSS)PLL
and Alg resulted in a stronger gel structure.
The DOX release kinetics from DOXPMO-NH2-Alg and
DOXPMO-PSS/PLL-Alg was investigated at diﬀerent incubation
time periods at pH 7.4 and pH 6.0 (Fig. 3, 4 and Tables S10, S11,
ESI†). The initial burst release of DOX from DOXPMO-NH2-Alg
and DOXPMO-PSS/PLL-Alg at pH 7.4 was about 23% and 15.0%
within the first 5 h (Fig. 3, 4 and Tables S10, S11, ESI†). On the
other hand, at pH 6.0, we observed a higher initial burst release
of DOX from DOXPMO-NH2-Alg and
DOXPMO-PSS/PLL-Alg
(around 32% and 28%, respectively), during the same period.
The release profiles of DOX from DOXPMO-NH2-Alg and
DOXPMO-PSS/PLL-Alg at pH 7.4 and 6.0 show a sustained and
extended release pattern (Fig. 3) after 5 h incubation.
We observed that more of the drug was released from
DOXPMO-NH2-Alg and
DOXPMO-PSS/PLL-Alg at an acidic pH
value, which is representative of a tumor tissue environment,
than at pH 7.4 in all incubation periods. For example, after
30 days, at pH 7.4 and at pH 6.0, DOXPMO-NH2-Alg/
DOXPMO-
PSS/PLL-Alg released 42%/29% and 66%/50% of the DOX,
respectively (Fig. 4 and Table S11, ESI†). This means 1.6/1.7 times
more DOX was released from DOXPMO-NH2-Alg/
DOXPMO-PSS/
PLL-Alg at pH 6.0 than at pH 7.4. In addition, after the same
incubation period, we investigated that at pH 7.4 and 6.0, almost
1.5/1.3 times more DOX was released from DOXPMO-NH2-Alg in
comparison with DOXPMO-PSS/PLL-Alg (Fig. 4 and Table S11, ESI†)
showing that the amount of drug released from the PMOs depends
on pH of the release environment and the surface coating of PMOs
Fig. 2 SEM images of NC hydrogels of (A) PMO-(PSS)PLL-Alg and (B) its
focus image, (C) DOXPMO-NH2-Alg and (D) its focus image, (E)
DOXPMO-
(PSS)PLL-Alg and (F) its focus image. (B, D and F) Are showing the
respective PMOs in the PMO-(PSS)PLL-Alg, DOXPMO-NH2-Alg, and
DOXPMO-(PSS)PLL-Alg.
Fig. 3 The amount of DOX (mg mL1) released from the DOXPMO-NH2-
Alg and DOXPMO-(PSS)/PLL-Alg scaﬀold over diﬀerent time intervals at
pH 7.4 and pH 6.0 (N = 6); data show significant diﬀerences; ANOVA:
p o 0.05 for all data.
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with polyelectrolytes, which considerably slowed the release rate
of DOX.
Alginate has been used successfully for the entrapment and/or
delivery of a variety of (bio)molecules, e.g. drugs, proteins, and for
the development of a controlled drug delivery system.18,28 In our
system the positively charged functional group on DOXPMO-NH2
and DOXPMO-PSS/PLL (DOX, NH2, PLL) can interact with the
carboxyl groups inalginate andultimately formDOX|Alg,DOX|PMO-
NH2|Alg and DOX|PMO-PSS/PLL|Alg complexes, and the release of
DOX from such composite hydrogel complexes become sustained
and pH dependent as the degradation of the hydrogel proceeds and
the electrostatic interactions between the charged components
change. Specifically, our pH-responsive DOXPMO-NH2-Alg and
DOXPMO-PSS/PLL-Alg allowed us to achieve prolonged release of
DOX and a prolonged release of a high dosage of DOX under
physiological and acidic conditions, respectively, that can be
also regulated via the polyelectrolyte coating on the PMOs.
Surface-mediated pH-responsive delivery of DOX to cancer and
healthy cells in NC scaﬀolds
Cell experiments were performed in the respective NC hydrogels to
study surface-mediated pH-controlled delivery of anti-cancer drug
molecules to cancer cells and healthy cells in a 3D matrix of
PMO-PSS/PLL-Alg, DOXPMO-NH2-Alg and
DOXPMO-PSS/PLL-Alg.
PMO-PSS/PLL-Alg was used as a control to analyse the eﬀect of
DOX on cell viability.
Primary healthy fibroblasts and malignant Colo 818 cells
(20 000 cells) were separately seeded into PMO-PSS/PLL-Alg,
DOXPMO-NH2-Alg and
DOXPMO-PSS/PLL-Alg and incubated for
various time intervals (30 min to 14 days) at 37 1C in cell culture
media at pH 7.4. After each incubation time, the number of
alive adherent cells and the cell viability in each of the scaﬀolds
were determined (Fig. 5, 6 and Table S12, ESI†).
We observed that DOX had a negative eﬀect on cell viability
already at the beginning of the experiment (Fig. 5, 6 and Table S12,
ESI†). After only 30 min incubation (Table S12, ESI†), the viability
of healthy cells (fibroblasts) and cancer cells (Colo 818) reduced to
75%/60% and 81%/76% in DOXPMO-NH2-Alg and
DOXPMO-PSS/
PLL-Alg, respectively. On the other hand, the viability of cells in
PMO-PSS/PLL-Alg was 93% (fibroblasts) and 84% (Colo 818).
Longer incubation times resulted in further decreases in cell
viability in each of the scaﬀolds (Fig. 6), but, interestingly,
the opposite trend was observed for the number of alive cells in
Fig. 4 The amount of DOX (in percentage) released from DOXPMO-NH2-
Alg (orange), and DOXPMO-(PSS)/PLL-Alg (green), at pH 7.4 (light color) and
6.0 (dark color) after 30 days [number of experiments (N) = 3; data show
significant diﬀerences; ANOVA: p o 0.001 (***)]. Fig. 5 The adhered amount of alive fibroblasts (light color) and Colo 818
(dark color) cells (103) on PMO-(PSS)/PLL-Alg (blue), DOXPMO-(PSS)/
PLL-Alg (green), and DOXPMO-NH2-Alg (orange) at diﬀerent incubation
time periods [number of repeated experiments (N) = 6; data show
significant diﬀerences; ANOVA: p o 0.001 (***)].
Fig. 6 The cell viability (%) of fibroblasts (light color) and Colo 818 (dark
color) cells on PMO-(PSS)/PLL-Alg (blue), DOXPMO-(PSS)/PLL-Alg (green),
and DOXPMO-NH2-Alg (orange) at diﬀerent incubation time periods
[number of repeated experiments (N) = 6; data show significant diﬀer-
ences; ANOVA: p o 0.001 (***)].
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PMO-PSS/PLL-Alg and DOXPMO-PSS/PLL-Alg (Fig. 5). After 14 days
of incubation, the number of cells in PMO-PSS/PLL-Alg and
DOXPMO-PSS/PLL-Alg increased (Fig. 5 and Table S12, ESI†),
although the cell viability was reduced (Fig. 6 and Table S12, ESI†).
Importantly, the number of alive cells and the cell viability was
(fibroblast/Colo818) less in DOXPMO-PSS/PLL-Alg than in PMO-PSS/
PLL-Alg due to the toxic eﬀects of DOX.29 On the other hand, we
observed a decrease both in the alive cell content and cell viability
in DOXPMO-NH2-Alg scaﬀold. We found, e.g., 3.5 times more alive
fibroblast cells and 2.2 times greater fibroblast cell viability
in DOXPMO-PSS/PLL-Alg than DOXPMO-NH2-Alg after 14 days of
incubation. These results indicate that the biopolymer coating at
the PMO surfaces enhanced cell growth. This means that while
DOX causes cell death, the PLL-coated PMO surfaces support cell
proliferation within the respective incubation periods.
More interestingly, we observed a considerable diﬀerence in
cell viability between fibroblast and Colo 818 cells in DOXPMO-
NH2-Alg and
DOXPMO-PSS/PLL-Alg scaﬀolds that was more
pronounced after 2 days of incubation (Fig. 6 and Table S12,
ESI†). The cancer cell (Colo 818) viability was ca. 19%/15% less
than that of the healthy cells (fibroblasts) in DOXPMO-NH2-Alg
and DOXPMO-PSS/PLL-Alg scaﬀolds. We attribute this diﬀerence
to the local acidic environment of the cancer cells, which
initiated the release of higher amounts of DOX from the
pH-responsive DOXPMO-NH2 and
DOXPMO-PSS/PLL than was
initiated in comparison to the healthy cell environment.
On the other hand, when we consider the numbers of alive
cancer cells and healthy cells, we recognized a significant
diﬀerence between DOXPMO-NH2-Alg and
DOXPMO-PSS/
PLL-Alg scaﬀolds (Fig. 5 and Table S12, ESI†). While an B18%
diﬀerence was observed in the number of alive cancer cells and
healthy cells in DOXPMO-PSS/PLL-Alg, a 41% diﬀerence was found
in DOXPMO-NH2-Alg after 14 days of incubation. This means that
the diﬀerence between the cell proliferation rate and the cell death
rate in DOXPMO-NH2-Alg was less significant than in
DOXPMO-PSS/
PLL-Alg, resulting in fewer alive cells with lower cell viability in
DOXPMO-NH2-Alg yet higher numbers of alive cells with lower cell
viability in DOXPMO-PSS/PLL-Alg.
In order to strengthen these results, we used the PrestoBlue
metabolic assay to monitor cell proliferation and cell viability
in PMO-PSS/PLL-Alg, DOXPMO-NH2-Alg and
DOXPMO-PSS/
PLL-Alg for diﬀerent incubation times (Fig. 7, 8 and Tables
S13, S14, ESI†). The results showed a continuous decrease in
metabolic activity and viability as a function of incubation time
in DOXPMO-NH2-Alg. On the other hand, we determined an
increase in cell proliferation in PMO-PSS/PLL-Alg and DOXPMO-
PSS/PLL-Alg even though there was also a continuous decrease
in cell viability, which was more pronounced in DOXPMO-PSS/
PLL-Alg than PMO-PSS/PLL-Alg.
Furthermore we used fluorescence microscopy to deter-
mined cell viability (Fig. 9 and 10) qualitatively. Since DOX
was internalized into the cells, dead cells was visualized by
microscope in red color and alive cells without color and by
overlapping the images, it was possible to determine the
amount of alive cells and dead cells at the same time. The
double staining (alive/dead) cell was also done which is shown
in Fig. 10. Calcein AM and propidium iodide were used as an
additional tool to show the ratio between alive and dead cells,
respectively.
Thus, these complementary results demonstrate that both
systems, DOXPMO-NH2-Alg and
DOXPMO-PSS/PLL-Alg, can be
Fig. 7 The amount of alive cells (103) of fibroblasts (light color), and
Colo 818 (dark color) in PMO-(PSS)/PLL-Alg (blue), DOXPMO-(PSS)/PLL-Alg
(green), and DOXPMO-NH2-Alg, (orange), and at diﬀerent incubation
time periods determined by the PrestoBlue assay [number of repeated
experiments (N) = 6; data show significant diﬀerences; ANOVA: p o 0.05 (*),
po 0.01 (**), po 0.001 (***)].
Fig. 8 The cell viability (%) of fibroblasts (light color), and Colo 818 (dark
color) cells in PMO-(PSS)/PLL-Alg (blue), DOXPMO-(PSS)/PLL-Alg (green),
and DOXPMO-NH2-Alg, (orange) at diﬀerent incubation time periods
determined by the PrestoBlue assay and a hemocytometer. [Number of
repeated experiments (N) = 6; data show significant diﬀerences; ANOVA:
p o 0.001 (***)].
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used for diﬀerent purposes. DOXPMO-PSS/PLL-Alg is the most
suitable system when the goal is to enhance cell proliferation
within the 3D biomaterial network and to have a slow drug
release rate; conversely, DOXPMO-NH2-Alg should be used when
the purpose is to administer fast and high dosage therapy.
Furthermore both systems are suitable for aﬀecting/damaging
cancer cells more than healthy cells when the cells have the
same exposure time to the drug.
Conclusions
In this study, we presented the preparation of pH-responsive
NC scaﬀolds DOXPMO-NH2-Alg and
DOXPMO-PSS/PLL-Alg, that
showed sustained and extended release of the DOX from PMOs
at pH 7.4 and pH 6.0. The respective cell experiments within
DOXPMO-NH2-Alg and
DOXPMO-PSS/PLL-Alg demonstrated an
improved cell adhesion in DOXPMO-PSS/PLL-Alg than DOXPMO-
NH2-Alg and a decrease in cell viability in both systems,
whereby there was a positive eﬀect of the biopolymer at the
PMO surfaces on cell proliferation and a toxic eﬀect of DOX on
the cells. Furthermore, we determined a diﬀerence in cell
viability between healthy cells and cancer cells due to the high
dosage release of DOX under acidic pH conditions than
physiological conditions. Therefore, we found less viability for
cancer Colo 818 cells than healthy fibroblasts due to the local
acidic environment of the Colo 818 cancer cells.
Overall, these results demonstrate that our pH-responsive
DOXPMO-NH2-Alg and
DOXPMO-PSS/PLL-Alg can potentially be
used in local drug delivery applications. DOXPMO-NH2-Alg can
be utilized in particular to deliver higher dosages of drug
molecules directly to cells, while DOXPMO-PSS/PLL is useful
for slow and prolonged release of drugs and for enhanced cell
adhesion. Nonetheless, both systems can be utilized to deliver
high dosages of drug molecules directly to cancer cells while
delivering less of the drug to healthy cells.
For future work, we will work on to increase the number
of polymer layer on PMOs and to increase the cross-linking
density of alginate to have a better control on the drug
Fig. 9 Fibroblasts (A–F) and Colo 818 (G–L) cells within DOXPMO-(PSS)/
PLL-Alg and DOXPMO-NH2-Alg scaffolds at 40 magnification (red: dead
cells by doxorubicin) after 7 days of incubation time (the arrows show the
alive cells).
Fig. 10 Fibroblasts (A and B) and Colo 818 (C and D) cells within DOXPMO-
(PSS)/PLL-Alg and DOXPMO-NH2-Alg scaﬀolds at 40 magnification
(red: dead cells by Propidium Iodide, green: alive cells by calcein AM) after
7 days of incubation time.
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molecules release and to slow down the initial burst release of
drug molecules.
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